Covid-19 vaccine (spikevax original-omicron ba 4-5 mrna)
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Vaccine containing COVID-19 (Spikevax Original/Omicron BA. 4-5 mRNA).
Drugs List
Therapeutic Indications
Uses
Coronavirus disease 2019 (COVID-19): Prophylaxis
For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.
Available at https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book
Dosage
Booster dose of COVID-19 vaccine (Spikevax Original-Omicron BA 4-5 mRNA) should be given at least 3 months after the completion of the primary series of COVID-19 vaccines.
Adults
1 dose (0.5ml).
Children
Children aged 12 years and over
1 dose (0.5ml).
Administration
Administered via intramuscular injection, preferably in the deltoid muscle.
Contraindications
Acute infection
Children under 12 years
Severe febrile conditions
Precautions and Warnings
Febrile disorder
Immunosuppression
Recent anticoagulant therapy
Coagulopathy
History of capillary leak syndrome
Immunodeficiency syndromes
Thrombocytopenia
Postpone immunisation if there is active or suspected infection
Advise ability to drive/operate machinery may be affected by side effects
Avoid second dose if anaphylaxis occurs with first dose
Impaired response possible in immunocompromised patients
Vaccine may not be effective in 100% of patients
Do not mix with other vaccines in the same syringe
Record name and batch number of administered product
Resuscitation facilities must be immediately available
Monitor for symptoms of Capillary Leak Syndrome
Monitor patient for at least 15 minutes after vaccination
Advise patient to inform their physician if dyspnoea/chest pain occur
Advise patient to report signs or symptoms of myocarditis and pericarditis
Advise patient to seek medical attention if new onset of heart palpitations
Follow national immunisation guidelines
Myocarditis and pericarditis can develop with a few days after vaccination, and have occurred primarily within 14 days, and observed more often after the second vaccination and in younger males.
Precautions should be in place to avoid injury from fainting should a psychogenic response occur from the needle injection.
Pregnancy and Lactation
Pregnancy
COVID-19 vaccine (Spikevax Original-Omicron BA 4-5 mRNA) is considered safe for use during pregnancy.
The manufacturer advises COVID-19 vaccine (Spikevax Original-Omicron BA 4-5 mRNA) may be used safely during pregnancy. Available reports indicate no increased risk of teratogenic or developmental effects.
Lactation
COVID-19 vaccine (Spikevax Original-Omicron BA 4-5 mRNA) is considered safe for use during breastfeeding.
The manufacturer states COVID-19 vaccine (Spikevax Original-Omicron BA 4-5 mRNA) may be used safely during breastfeeding. The presence of COVID-19 vaccine (Spikevax Original-Omicron Bivalent mRNA) in breastmilk is unknown. Studies of breastfed infants exposed to COVID-19 vaccine (Spikevax Original-Omicron BA 4-5 mRNA) have shown no adverse effects.
Side Effects
Abdominal pain
Anaphylaxis
Arthralgia
Axillary swelling
Axillary tenderness
Chills
Decreased appetite
Delayed injection site reaction
Diarrhoea
Dizziness
Erythema at injection site
Erythema multiforme
Facial paralysis
Facial swelling
Fatigue
Headache
Hypersensitivity reactions
Hypoaesthesia
Irritability
Local pain (injection site)
Lymphadenopathy
Menstrual bleeding increased
Myalgia
Myocarditis
Nausea
Paraesthesia
Pericarditis
Pyrexia
Rash
Sleepiness
Slight redness of the skin
Swelling (injection site)
Swelling(localised)
Urticaria
Vomiting
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: January 2023
Reference Sources
Summary of Product Characteristics: Spikevax bivalent Original/Omicron BA.4-5 dispersion for injection. Moderna. Revised December 2022.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.